FGFR-based Bispecific ADCs

FGFR-based bispecific ADCs (Antibody-Drug Conjugates) are an emerging class of targeted cancer therapies designed to enhance treatment specificity and efficacy. By leveraging fibroblast growth factor receptors (FGFRs) as key binding targets, these bispecific ADCs can simultaneously engage multiple tumor-associated antigens, improving drug delivery and minimizing off-target effects. As research in FGFR-based Bispecific ADCs advances, they hold great promise for treating FGFR-driven malignancies, including certain types of lung, bladder, and gastric cancers.